Pfizer
Pfizer Discontinues Hemophilia B Gene Therapy Beqvez, Exits Gene Therapy Field
Pfizer, Beqvez, hemophilia B, gene therapy, discontinuation, portfolio exit
Ex-CDER chief Patrizia Cavazzoni becomes Pfizers chief medical officer
Patrizia Cavazzoni, Pfizer ‘s, Pfizer, Cavazzoni
Pfizer taps former FDA drug chief Cavazzoni as new CMO
United States Food and Drug Administration, Pfizer, Cavazzoni, Center for Drug Evaluation and Research, Appointments, President brand of dental material
Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations
Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials
BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment
Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy
Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns
Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption
GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market
Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults
FDA Approves Pfizer’s Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma
Adcetris, brentuximab vedotin, FDA approval, large B-cell lymphoma, LBCL, DLBCL, antibody-drug conjugate, Pfizer, combination therapy
Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement
Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs
Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer
Pfizer, Jeffrey Legos, Novartis, oncology, pharmaceutical industry, leadership change, cancer research